VaccineDanmark.dk ApS: Financial statements 2023
CVR: 42460699
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
VaccineDanmark.dk ApS (CVR 42460699) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -193,116 and a net result of DKK -272,101 compared with DKK 5,990,891 the year before. Equity in the 2023 report amounted to DKK 5,758,790. The solvency ratio was 70.7%.
- Gross Profit
- DKK -193,116
- Profit/Loss
- DKK -272,101
- Equity
- DKK 5,758,790
- Total Assets
- DKK 8,141,893
- Employees
- 0
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
VaccineDanmark.dk ApS has published its annual report for 2022. Gross profit came to DKK 11,472,642, and the net result was DKK 5,990,891.
As of January 13, 2023, AROS STATSAUTORISEREDE REVISORER I/S has been appointed auditor of VaccineDanmark.dk ApS.
About VaccineDanmark.dk ApS
VaccineDanmark.dk ApS is a Danish company of the type Anpartsselskab based in Herning, founded in 2021. The company is registered under the industry Speciallægers aktiviteter. The management consists of Damir Drljevic. The company is owned by DRDAM ApS. The company has 9 employees (2022). In 2025, the company reported a gross profit of DKK -21,698 and a net result of DKK -26,385 compared with DKK -185,176 the year before. Equity in the 2025 report amounted to DKK -152,771.